• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves first nasally administered pharmaceutical treatment for dry eye

October 25, 2021 By Sean Whooley

Aptar Pharma Oyster Point CPS Tyrvaya
[Image from Aptar Pharma]
AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye.

Crystal Lake, Illinois–based Aptar said the patented Cartridge Pump System (CPS) is for the multidose delivery of preserved and non-preserved drug formulations. It has received approval as the device for delivering Oyster Point Pharma’s Tyrvaya (varenicline solution) nasal spray (0.03 mg).

According to a news release, Tyrvaya delivered with Aptar’s CPS becomes the first and only nasal spray approved for treating signs and symptoms of dry eye disease in the U.S.

“This approval further demonstrates the broad potential for Aptar’s drug delivery solutions and the continued market opportunities for nasal drug delivery,” Aptar President & CEO Stephan B. Tanda said in the release.

Approval for Tyrvaya with the CPS included a combination product submission by Oyster Point to the FDA, which benefitted from Aptar Pharma’s portfolio of stage-specific development packages, the company said. Aptar’s regulatory affairs professionals and analytical scientists helped customers proactively address regulatory needs to accelerate approval, too.

“We are pleased that Aptar Pharma’s CPS Technology has been successfully reviewed by the U.S. FDA for Oyster Point Pharma’s therapy for the treatment of the signs and symptoms of dry eye disease via the nose,” Aptar Pharma President Gael Touya said. “This project once again underlines Aptar Pharma’s ability to develop and deliver complex drug delivery systems, and demonstrates our expertise in partnering with customers through their successful drug development journeys.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: aptarpharma, FDA, oysterpointpharma

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS